ESMO Breast Cancer
<ѻý class="page-description">European Society for Medical Oncologyѻý>No difference in survival versus chemotherapy alone in patients with PD-L1-positive disease
May 16, 2024
No PFS benefit with addition of ceralasertib to olaparib
May 5, 2022
High intracranial response rates with trastuzumab-deruxtecan observed in TUXEDO-1 trial
May 4, 2022
<ѻý class="section_title"> Latest Oncology/Hematology Meeting Coverageѻý>
-
ASTRO: American Society for Radiation Oncology
September 2024
-
ESMO: European Society for Medical Oncology
September 2024
-
ASCO: American Society of Clinical Oncology
May 2024
-
AACR: American Association for Cancer Research
April 2024